Success Metrics

Clinical Success Rate
90.1%

Based on 218 completed trials

Completion Rate
90%(218/242)
Active Trials
20(7%)
Results Posted
33%(72 trials)
Terminated
24(8%)

Phase Distribution

Ph phase_1
93
32%
Ph phase_2
160
55%
Ph phase_4
1
0%
Ph early_phase_1
1
0%
Ph not_applicable
9
3%
Ph phase_3
27
9%

Phase Distribution

94

Early Stage

160

Mid Stage

28

Late Stage

Phase Distribution291 total trials
Early Phase 1First-in-human
1(0.3%)
Phase 1Safety & dosage
93(32.0%)
Phase 2Efficacy & side effects
160(55.0%)
Phase 3Large-scale testing
27(9.3%)
Phase 4Post-market surveillance
1(0.3%)
N/ANon-phased studies
9(3.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.2%

218 of 250 finished

Non-Completion Rate

12.8%

32 ended early

Currently Active

20

trials recruiting

Total Trials

291

all time

Status Distribution
Active(22)
Completed(218)
Terminated(32)
Other(19)

Detailed Status

Completed218
Terminated24
unknown17
Recruiting10
Active, not recruiting10
Withdrawn8

Development Timeline

Analytics

Development Status

Total Trials
291
Active
20
Success Rate
90.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.3%)
Phase 193 (32.0%)
Phase 2160 (55.0%)
Phase 327 (9.3%)
Phase 41 (0.3%)
N/A9 (3.1%)

Trials by Status

unknown176%
terminated248%
completed21875%
not_yet_recruiting21%
suspended21%
recruiting103%
active_not_recruiting103%
withdrawn83%

Recent Activity

Clinical Trials (291)

Showing 20 of 291 trialsScroll for more
NCT07085338Phase 2

A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma

Recruiting
NCT07169617Phase 2

Testing the SurVaxM Vaccine for Lung Cancer Prevention

Not Yet Recruiting
NCT03786783Phase 2

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Completed
NCT02339571Phase 2

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Active Not Recruiting
NCT01134614Phase 2

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Active Not Recruiting
NCT06202066Phase 2

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Recruiting
NCT02334865Phase 1

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Active Not Recruiting
NCT05455658Phase 2

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Active Not Recruiting
NCT04902703Phase 2

Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease

Recruiting
NCT00669734Phase 1

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

Active Not Recruiting
NCT04237623Phase 2

GM-CSF With Post-Transplant Cyclophosphamide

Recruiting
NCT07437963Phase 1

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

Not Yet Recruiting
NCT02455557Phase 2

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Active Not Recruiting
NCT07078604Phase 2

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Recruiting
NCT05269381Phase 1

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Recruiting
NCT00026312Phase 3

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Completed
NCT03126916Phase 3

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Recruiting
NCT03794349Phase 2

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Active Not Recruiting
NCT06528496Phase 2

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Recruiting
NCT03879694Phase 1

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Completed

Drug Details

Intervention Type
DRUG
Total Trials
291